U Of U Hospitals & Clinics
- Type
- Teaching hospital
- Where
- Salt Lake City, UT
- Medicare CCN
- 460009
- Received
- $34,982,734 in 2,581 records, 2024 ($3,840,742 general, $31,141,991 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2024 | General payment | 248 | $3,840,742 |
| 2024 | Research payment | 2,333 | $31,141,991 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 2,333 | $31,141,991 |
| Grant | 71 | $2,723,244 |
| Space rental or facility fees (teaching hospital only) | 87 | $402,347 |
| Debt forgiveness | 26 | $173,188 |
| Royalty or License | 8 | $167,515 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 25 | $135,338 |
| Long term medical supply or device loan | 12 | $115,557 |
| Education | 11 | $66,306 |
| Consulting Fee | 5 | $50,944 |
| Charitable Contribution | 3 | $6,300 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2024-12-31 | Merck Sharp & Dohme LLC | $531,714 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $454,672 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $226,095 | Research payment | Cash or cash equivalent | WINREVAIR Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $145,274 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV in Comb | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $143,029 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $84,151 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $60,232 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | 2024 |
| 2024-12-31 | Siemens Medical Solutions USA, Inc. | $55,818 | Research payment | In-kind items and services | Multitom Rax Device, DI - X-Ray Products | Assessment of novel 3D imaging features of Multitom Rax | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $41,732 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Safety and Efficacy of Pembrolizumab plus Enfortumab Vedotin EV i | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $29,496 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1,2 Randomized, Umbrella Study to Evaluate the Efficacy and Safety of MK-2870 Plus Enfortumab Vedotin EV in Comb | 2024 |
| 2024-12-31 | AstraZeneca Pharmaceuticals LP | $26,931 | Research payment | In-kind items and services | A Phase 1 Dose Escalation and Expansion Study of AZD9833 Alone or in Combination with Palbociclib in Women with ER Posit | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $18,589 | Research payment | In-kind items and services | LENVIMA Drug, ONCOLOGY | A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib E7080,MK-79 | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $16,890 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | LIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $16,850 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $14,107 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib MK-7902 vs Cabozantinib for Treatment | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $14,006 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Stand | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $12,934 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $11,346 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | A Multicenter, Open-label, Randomized, Phase 1,2 Study of Belzutifan in Combination with Palbociclib Versus Belzutifan M | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $10,073 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab MK-3475 and Pembrolizumab in Combination wit | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $8,762 | Research payment | In-kind items and services | Drug, INFECTIOUS DISEASE | A Phase 2b,3 Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-1654 in Health | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $7,764 | Research payment | In-kind items and services | GARDASIL 9 Biological, VACCINE | A Phase 3, Multicenter, Open-Label Study to Evaluate the Safety and Immunogenicity of 2-dose Regimens of 9vHPV and mRNA- | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $6,253 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $5,349 | Research payment | In-kind items and services | WELIREG Drug, ONCOLOGY | Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $5,000 | Education | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Merck Sharp & Dohme LLC | $4,089 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2024 |
| 2024-12-31 | Intuitive Surgical, Inc. | $3,400 | Long term medical supply or device loan | In-kind items and services | DAVINCI XI Device, SURGERY | 2024 | |
| 2024-12-31 | Sumitomo Pharma America, Inc. | $3,018 | Research payment | Cash or cash equivalent | A Phase 1/2, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Oral Nuvisertib (TP-3654 | 2024 | |
| 2024-12-31 | ABBVIE INC. | $1,750 | Research payment | In-kind items and services | A Phase I Study of ABBV-011 as a Single-Agent and in Combination with Budigalimab (ABBV-181) in Subjects with Relapsed o | 2024 | |
| 2024-12-31 | ABBVIE INC. | $1,656 | Research payment | In-kind items and services | VYALEV Drug, NEUROSCIENCE | M20-098 ABBV-951 aPD | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $1,617 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background Pulmonary Arteri | 2024 |
| 2024-12-31 | ABBVIE INC. | $1,320 | Research payment | In-kind items and services | UBRELVY Drug, NEUROSCIENCE | 3110-305-002 Ph3 Pivotal Peds Post Approval - PMR (M21-265) | 2024 |
| 2024-12-31 | Regeneron Pharmaceuticals, Inc. | $890 | Research payment | Cash or cash equivalent | LIBTAYO Biological, ONCOLOGY | I-SPY 2 TRIAL (INVESTIGATION OF SERIAL STUDIES TO PREDICT YOUR THERAPEUTIC RESPONSE WITH IMAGING AND MOLECULAR ANALYSIS | 2024 |
| 2024-12-31 | Stryker Corporation | $870 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Philips North America LLC | $732 | Long term medical supply or device loan | In-kind items and services | (8269) DreamStation Cpap Device, Medical Device | 2024 | |
| 2024-12-31 | ABBVIE INC. | $600 | Research payment | In-kind items and services | M23-385 ABBV-706 Ph 1 2L-4L SCLC | 2024 | |
| 2024-12-31 | Acerta Pharma LLC | $592 | Research payment | In-kind items and services | CALQUENCE Drug, Oncology | A Phase half, Multicenter, Open-label, and Dose-escalation Study of ACP-196 in Subjects with Chronic Lymphocytic Leukemi | 2024 |
| 2024-12-31 | Merck Sharp & Dohme LLC | $586 | Research payment | In-kind items and services | WINREVAIR Biological, CARDIOVASCULAR | A Phase 3, Randomized Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary | 2024 |
| 2024-12-31 | ABBVIE INC. | $392 | Research payment | In-kind items and services | A Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate the Safety, Tolerability, and Pharmacodynamics of CVL-8 | 2024 | |
| 2024-12-31 | Sumitomo Pharma America, Inc. | $360 | Research payment | Cash or cash equivalent | A Phase 1 Study of DSP-0390 in Patients with Recurrent High-grade Glioma | 2024 | |
| 2024-12-31 | Stryker Corporation | $176 | Debt forgiveness | Cash or cash equivalent | 2024 | ||
| 2024-12-31 | Merck Sharp & Dohme LLC | $76 | Research payment | In-kind items and services | SIVEXTRO Drug, INFECTIOUS DISEASE | A Phase 1, Single- and Multiple-Dose Safety and Pharmacokinetic Study of Oral and IV Tedizolid Phosphate MK-1986 in Inpa | 2024 |
| 2024-12-31 | Stryker Corporation | $55 | Long term medical supply or device loan | In-kind items and services | CORE Device, INSTRUMENTS | 2024 | |
| 2024-12-30 | Janssen Research & Development, LLC | $70,758 | Research payment | Cash or cash equivalent | ERLEADA Drug, Oncology | A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Depriva | 2024 |
| 2024-12-30 | ABBVIE INC. | $21,198 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2024 |
| 2024-12-30 | Intuitive Surgical, Inc. | $16,000 | Consulting Fee | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-12-30 | ABBVIE INC. | $5,744 | Research payment | Cash or cash equivalent | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination Wi | 2024 | |
| 2024-12-30 | Janssen Research & Development, LLC | $4,368 | Research payment | Cash or cash equivalent | A Phase 1 Dose Escalation Study of JNJ75229414 a Chimeric Antigen Receptor T cell CART Therapy Directed Against KLK2 for | 2024 | |
| 2024-12-30 | Janssen Research & Development, LLC | $3,300 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-12-30 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2024 |
| 2024-12-30 | Janssen Research & Development, LLC | $557 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-12-30 | Janssen Research & Development, LLC | $355 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-12-28 | Biogen, Inc. | $1,000 | Grant | Cash or cash equivalent | 2024 | ||
| 2024-12-27 | Boston Scientific Corporation | $35,000 | Grant | Cash or cash equivalent | Device, General - Therapies_ENDO | 2024 | |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $2,700 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $2,500 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $2,500 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $2,200 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $2,200 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $1,837 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $1,537 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | Janssen Research & Development, LLC | $1,500 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2024 |
| 2024-12-27 | Medacta USA, Inc. | $816 | Research payment | Cash or cash equivalent | M-Vizion Femoral Revision System Device, HIP | Medacta M-Vizion Macroscopic Radiographic Study, Multi-center, Post-Market Outcomes Study | 2024 |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $800 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $405 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | Sarepta Therapeutics, Inc. | $318 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-27 | AKEBIA THERAPEUTICS INC | $241 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-27 | Sarepta Therapeutics, Inc. | $93 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-27 | Sarepta Therapeutics, Inc. | $25 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-26 | Biogen, Inc. | $336,911 | Research payment | Cash or cash equivalent | SPINRAZA Biological, Neurology | An Open-Label Extension Study for Patients With Spinal Muscular AtrophyWho Previously Participated in Investigational St | 2024 |
| 2024-12-26 | Amicus Therapeutics, Inc. | $19,063 | Research payment | Cash or cash equivalent | POMBILITI Drug, Pompe Disease | A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD | 2024 |
| 2024-12-26 | Sarepta Therapeutics, Inc. | $3,343 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-26 | Janssen Research & Development, LLC | $327 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide Bortezo | 2024 |
| 2024-12-24 | ABBVIE INC. | $15,021 | Research payment | Cash or cash equivalent | UBRELVY Drug, NEUROSCIENCE | Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Ch | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $7,209 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $5,265 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $3,082 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-24 | United Therapeutics Corporation | $2,363 | Research payment | Cash or cash equivalent | TYVASO Drug, Idiopathic Pulmonary Fibrosis | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2024 |
| 2024-12-23 | Merck Sharp & Dohme LLC | $228,519 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Thera | 2024 |
| 2024-12-23 | Genentech, Inc. | $18,619 | Research payment | Cash or cash equivalent | Cotellic Drug, BioOncology | Cobimetinib in patients with RAS activated CMML | 2024 |
| 2024-12-23 | Janssen Research & Development, LLC | $7,143 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-12-23 | Janssen Research & Development, LLC | $3,110 | Research payment | Cash or cash equivalent | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitre | 2024 | |
| 2024-12-22 | Philips North America LLC | $5,459 | Research payment | In-kind items and services | (3082) NIBP Cuffs Device, Medical Device | Non-Invasive Blood Pressure Validation Study | 2024 |
| 2024-12-20 | Genentech, Inc. | $150,000 | Research payment | Cash or cash equivalent | 2024 | ||
| 2024-12-20 | PFIZER INC. | $10,378 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-12-20 | Blueprint Medicines Corporation | $5,406 | Research payment | Cash or cash equivalent | A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients | 2024 | |
| 2024-12-20 | Blueprint Medicines Corporation | $1,925 | Research payment | Cash or cash equivalent | A Phase 1/2, open-label, 2-arm study evaluating BLU-263 as monotherapy and in combination with azacitidine, in patients | 2024 | |
| 2024-12-20 | Daiichi Sankyo Inc. | $1,565 | Research payment | Cash or cash equivalent | DS1103-074 | 2024 | |
| 2024-12-19 | AstraZeneca UK Limited | $52,694 | Research payment | Cash or cash equivalent | SAPHNELO Biological, Inflammation and Autoimmunity | A Phase III,Randomized,Double blind,Parallel group,Placebo controlled Study to Evaluate the Pharmacokinetics,Pharmacodyn | 2024 |
| 2024-12-19 | ABBVIE INC. | $9,549 | Research payment | Cash or cash equivalent | UBRELVY Drug, NEUROSCIENCE | Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migrai | 2024 |
| 2024-12-19 | Janssen Research & Development, LLC | $3,689 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Pred | 2024 | |
| 2024-12-19 | Janssen Research & Development, LLC | $2,510 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Study Comparing Talquetamab SC in Combination WithDaratumumab SC and Pomalidomide (Tal-DP) or Talqu | 2024 | |
| 2024-12-19 | Epizyme, Inc. | $2,476 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2024 |
| 2024-12-19 | Epizyme, Inc. | $2,394 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2024 |
| 2024-12-19 | CSL Behring | $2,342 | Research payment | Cash or cash equivalent | HEMGENIX Biological, Hematology | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral | 2024 |
| 2024-12-19 | Neurelis, Inc. | $2,000 | Education | Cash or cash equivalent | VALTOCO Drug, EPILEPSY | 2024 | |
| 2024-12-19 | Ipsen Pharma SAS | $1,835 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-12-19 | Ipsen Pharma SAS | $1,835 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2024 |
| 2024-12-19 | Epizyme, Inc. | $1,333 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2024 |
| 2024-12-19 | Epizyme, Inc. | $1,333 | Research payment | Cash or cash equivalent | Tazverik Drug, Oncology | Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat | 2024 |
| 2024-12-18 | UCB SA | $14,584 | Research payment | Cash or cash equivalent | A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFE | 2024 | |
| 2024-12-18 | BioMarin Pharmaceutical Inc. | $13,063 | Research payment | Cash or cash equivalent | PALYNZIQ Drug, PKU | Phase 3 substudy enrolling approximately 100 subjects aged 18 to 70 years old with PKU who are concurrently participatin | 2024 |
| 2024-12-18 | AstraZeneca UK Limited | $12,284 | Research payment | Cash or cash equivalent | FASENRA Biological, Respiratory | A Multicentre Randomised Double-blind Parallel-group Placebo-controlled 24-week Phase 3 Study with an Open-label Extensi | 2024 |
| 2024-12-18 | Scientia Vascular | $8,000 | Research payment | Cash or cash equivalent | Colossus Device, Neuro | Research Grant - Colossus Posterior and Educational Research Grant | 2024 |
| 2024-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $750 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2024 | |
| 2024-12-18 | Takeda Pharmaceuticals U.S.A., Inc. | $341 | Research payment | Cash or cash equivalent | A PHASE 4 STUDY EVALUATING REAL-WORLD USE OF CDPATH?, A CROHN'S DISEASE RISK PREDICTION TOOL | 2024 | |
| 2024-12-17 | Boston Scientific Corporation | $692,749 | Grant | In-kind items and services | Device, General - Therapies_ENDO | 2024 | |
| 2024-12-17 | Astellas US Technologies | $224,720 | Research payment | In-kind items and services | Padcev Drug, Oncology | ENCORE: A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with | 2024 |
| 2024-12-17 | Medtronic, Inc. | $103,076 | Research payment | Cash or cash equivalent | ONYX 18 Device, Liquid Embolics | EMBOLISE | 2024 |
| 2024-12-17 | PFIZER INC. | $19,854 | Research payment | Cash or cash equivalent | PAXLOVID Drug, INFECTIOUS DISEASES | A PHASE 23 INTERVENTIONAL SAFETY PHARMACOKINETICS AND EFFICACY OPENLABEL MULTICENTER SINGLEARM STUDY TO INVESTIGATE ORAL | 2024 |
| 2024-12-17 | Medical Device Business Services, Inc. | $6,262 | Research payment | Cash or cash equivalent | HEALIX KNOTLESS PEEK Device, Sports Surgical | Mitek Device Registry | 2024 |
| 2024-12-17 | Medical Device Business Services, Inc. | $1,977 | Research payment | Cash or cash equivalent | HEALIX KNOTLESS PEEK Device, Sports Surgical | Mitek Device Registry | 2024 |
| 2024-12-17 | Medical Device Business Services, Inc. | $900 | Research payment | Cash or cash equivalent | HEALIX KNOTLESS PEEK Device, Sports Surgical | Mitek Device Registry | 2024 |
| 2024-12-17 | Medical Device Business Services, Inc. | $600 | Research payment | Cash or cash equivalent | HEALIX KNOTLESS PEEK Device, Sports Surgical | Mitek Device Registry | 2024 |
| 2024-12-17 | Boston Scientific Corporation | $495 | Research payment | Cash or cash equivalent | TACTRA Device, TACTRA_URO | IT MATTERS | 2024 |
| 2024-12-16 | PFIZER INC. | $44,921 | Research payment | Cash or cash equivalent | A PHASE 1 STUDY OF SGNEGFRD2 IN ADVANCED SOLID TUMORS | 2024 | |
| 2024-12-16 | Janssen Research & Development, LLC | $9,037 | Research payment | Cash or cash equivalent | A Phase 3 Randomized Placebo controlled Double blind Study of Niraparib in Combination with Abiraterone Acetate and Pred | 2024 | |
| 2024-12-16 | Janssen Research & Development, LLC | $8,866 | Research payment | Cash or cash equivalent | CARVYKTI Drug, Oncology | A Phase 2 Multicohort Open Label Study of JNJ68284528 a Chimeric Antigen Receptor T cell CART Therapy Directed Against B | 2024 |
| 2024-12-16 | PFIZER INC. | $3,513 | Research payment | Cash or cash equivalent | PADCEV Biological, Oncology | AN OPENLABEL RANDOMIZED CONTROLLED PHASE 3 STUDY OF ENFORTUMAB VEDOTIN IN COMBINATION WITH PEMBROLIZUMAB VERSUS CHEMOTHE | 2024 |
| 2024-12-16 | Janssen Research & Development, LLC | $2,918 | Research payment | Cash or cash equivalent | A Phase 2/3, Randomized, Double-masked, Multicenter, Dose-ranging, Sham-controlled Clinical Trial to Evaluate Intravitre | 2024 | |
| 2024-12-16 | Lucid Diagnostics Inc. | $750 | Research payment | Cash or cash equivalent | BE2 | 2024 | |
| 2024-12-16 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-12-16 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-12-16 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | IBRANCE Drug, ONCOLOGY | PALLASPALBOCICLIB COLLABORATIVE ADJUVANT STUDYA RANDOMIZED PHASE III TRIAL OF PALBOCICLIB WITH STANDARD ADJUVANT ENDOCRI | 2024 |
| 2024-12-13 | Amicus Therapeutics, Inc. | $122,075 | Research payment | Cash or cash equivalent | POMBILITI Drug, Pompe Disease | A Study to Assess the Long-term Safety and Efficacy of ATB200/AT2221 in Adult Subjects With LOPD | 2024 |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $11,000 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $10,800 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Merck Sharp & Dohme LLC | $10,800 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | LIGHTBEAM-U01 Substudy 01B# A Phase 1,2 Substudy to Evaluate the Safety and Efficacy of Pembrolizumab in Combination Wit | 2024 |
| 2024-12-13 | Janssen Research & Development, LLC | $5,706 | Research payment | Cash or cash equivalent | TECVAYLI Biological, Oncology | A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC (Tec-Dara) versus Daratumumab SC, Po | 2024 |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $5,486 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $5,400 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Janssen Research & Development, LLC | $3,335 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $2,500 | Research payment | Cash or cash equivalent | A STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT | 2024 | |
| 2024-12-13 | Medical Device Business Services, Inc. | $2,300 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-13 | Sarepta Therapeutics, Inc. | $2,184 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Janssen Research & Development, LLC | $1,925 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $1,785 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $1,785 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $1,538 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $1,350 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $1,225 | Research payment | Cash or cash equivalent | A STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT | 2024 | |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $800 | Research payment | Cash or cash equivalent | A STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $675 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $445 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $445 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $257 | Research payment | Cash or cash equivalent | A STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT | 2024 | |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $257 | Research payment | Cash or cash equivalent | A STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Takeda Pharmaceuticals U.S.A., Inc. | $250 | Research payment | Cash or cash equivalent | A STUDY OF TAK-755 (RADAMTS13) WITH LITTLE TO NO PLASMA EXCHANGE (PEX) TREATMENT IN ADULTS WITH IMMUNE-MEDIATED THROMBOT | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $250 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | Sarepta Therapeutics, Inc. | $200 | Research payment | Cash or cash equivalent | SRP-9001-305 | 2024 | |
| 2024-12-13 | CSL Behring | $71 | Research payment | In-kind items and services | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral | 2024 | |
| 2024-12-12 | Novavax Inc | $268,885 | Research payment | Cash or cash equivalent | NOVAVAX COVID-19 VACCINE, ADJUVANTED Biological, vaccine | Study of Health care workers and First Responders Investigating Effects of Systemic and Local reactogenicity of COVID-19 | 2024 |
| 2024-12-12 | Alexion Pharmaceuticals, Inc. | $100,000 | Research payment | Cash or cash equivalent | Epidemiology and Characterization of Serum Biomarkers of Autoimmunity in NMOSD Patients from the United States Departmen | 2024 | |
| 2024-12-12 | ABBVIE INC. | $42,908 | Research payment | Cash or cash equivalent | SKYRIZI Biological, IMMUNOLOGY | A Study to Assess Adverse Events Change in Disease Activity and How the Drug Moves Through the Body in Children With Juv | 2024 |
| 2024-12-12 | Sebela Women's Health Inc. | $4,282 | Research payment | Cash or cash equivalent | A PHASE 3, PROSPECTIVE, MULTI-CENTER, SINGLE-ARM, OPEN-LABEL STUDY TO EVALUATE VERACEPT, A LONG-ACTING REVERSIBLE INTRAU | 2024 | |
| 2024-12-12 | Regeneron Pharmaceuticals, Inc. | $2,725 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIEN | 2024 |
| 2024-12-12 | Regeneron Pharmaceuticals, Inc. | $1,851 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIEN | 2024 |
| 2024-12-12 | Regeneron Pharmaceuticals, Inc. | $200 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A PHASE 2/3, RANDOMIZED, 3-PART STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF DUPILUMAB IN ADULT AND ADOLESCENT PATIEN | 2024 |
| 2024-12-11 | Intuitive Surgical, Inc. | $16,000 | Consulting Fee | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | 2024 | |
| 2024-12-11 | Ultragenyx Pharmaceutical Inc. | $5,163 | Research payment | Cash or cash equivalent | DTX401-CL301 | 2024 | |
| 2024-12-11 | Novo Nordisk Inc | $5,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-11 | Takeda Pharmaceuticals U.S.A., Inc. | $2,700 | Research payment | Cash or cash equivalent | A STUDY OF SOTICLESTAT AS AN ADD-ON THERAPY IN CHILDREN AND ADULTS WITH DRAVET SYNDROME OR LENNOX-GASTAUT SYNDROME | 2024 | |
| 2024-12-11 | Smith+Nephew, Inc. | $2,344 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | ENDOBUTTON Device, Sports Med Knee | 2024 | |
| 2024-12-11 | AKEBIA THERAPEUTICS INC | $2,200 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-11 | KLS-Martin L.P. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2024 | ||
| 2024-12-11 | AKEBIA THERAPEUTICS INC | $1,875 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-11 | SPR Therapeutics, Inc | $1,542 | Research payment | Cash or cash equivalent | SPRINT PNS System Device, Pain Management | The MONARCH (Multicenter Occipital Neuralgia and Cervicogenic Headache) Case Series Study: Treatment of Head Pain with t | 2024 |
| 2024-12-11 | AKEBIA THERAPEUTICS INC | $1,225 | Research payment | Cash or cash equivalent | Auryxia Drug, Nephrology | A 36-week, Single-Arm, Open-label Study to Evaluate the Safety and Tolerability of Ferric Citrate in Children With Hyper | 2024 |
| 2024-12-11 | Day One Biopharmaceuticals | $778 | Research payment | Cash or cash equivalent | OJEMDA Drug, ONCOLOGY | DAY101-001/PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inh | 2024 |
| 2024-12-11 | Day One Biopharmaceuticals | $631 | Research payment | Cash or cash equivalent | OJEMDA Drug, ONCOLOGY | DAY101-001/PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inh | 2024 |
| 2024-12-11 | Day One Biopharmaceuticals | $130 | Research payment | Cash or cash equivalent | OJEMDA Drug, ONCOLOGY | DAY101-001/PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inh | 2024 |
| 2024-12-11 | Day One Biopharmaceuticals | $102 | Research payment | Cash or cash equivalent | OJEMDA Drug, ONCOLOGY | DAY101-001/PNOC026: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inh | 2024 |
| 2024-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | $49,417 | Research payment | Cash or cash equivalent | PhII - BI 1839100 in IPF associated with chronic cough | 2024 | |
| 2024-12-10 | ABK Biomedical USA, Inc. | $24,770 | Research payment | Cash or cash equivalent | Eye90 microspheres Device, Radiation Therapy Devices | Radioembolization Oncology Trial Utilizing Transarterial Eye90 (ROUTE 90) for the Treatment of Hepatocellular Carcinoma | 2024 |
| 2024-12-10 | Ipsen Pharma SAS | $203 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Prospective, Multicountry Study to Estimate the Incidence of and Provide a Best Practice Model for Monitoring the Deve | 2024 |
| 2024-12-09 | Astellas US Technologies | $140,450 | Research payment | In-kind items and services | Padcev Drug, Oncology | ENCORE: A Phase 2 Umbrella Protocol of Enfortumab Vedotin as Monotherapy and Combined with Other Agents in Patients with | 2024 |
| 2024-12-09 | Janssen Research & Development, LLC | $81,423 | Research payment | Cash or cash equivalent | An Open label Phase 11b Study to Evaluate the Safety and Pharmacokinetics of JNJ73841937 Lazertinib a Third Generation E | 2024 | |
| 2024-12-09 | Janssen Research & Development, LLC | $11,415 | Research payment | Cash or cash equivalent | A Phase 1 Study of JNJ69086420 an Actinium225Labeled Antibody Targeting Human Kallikren2 hK2 for Advanced Prostate Cance | 2024 | |
| 2024-12-09 | GENZYME CORPORATION | $5,690 | Research payment | Cash or cash equivalent | A Phase 3, Single-arm, Multicenter, Multinational, Open-label, One-way Crossover Study to Investigate the Efficacy and S | 2024 | |
| 2024-12-09 | Olympus America Inc. | $1,214 | Debt forgiveness | In-kind items and services | 2024 | ||
| 2024-12-09 | CSL Behring | $256 | Research payment | In-kind items and services | An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administ | 2024 | |
| 2024-12-06 | Takeda Pharmaceuticals U.S.A., Inc. | $20,300 | Research payment | Cash or cash equivalent | VPRIV Biological, GENETIC DISEASE | GAUCHER DISEASE OUTCOME SURVEY (GOS) AN OBSERVATIONAL, INTERNATIONAL, MULTICENTER, LONG-TERM REGISTRY OF PATIENTS WITH G | 2024 |
| 2024-12-06 | Stryker Corporation | $15,233 | Research payment | Cash or cash equivalent | INSIGNIA Device, JOINT REPLACEMENT HIPS, KNEES | EARLY PERFORMANCE OF THE INSIGNIA STEM IN PRIMARY DIRECT ANTERIOR TOTAL HIP ARTHROPLASTY | 2024 |
| 2024-12-06 | Agios Pharmaceuticals, Inc. | $15,046 | Research payment | Cash or cash equivalent | PYRUKYND Drug, Genetically Defined Disease | AG348-C-011 | 2024 |
| 2024-12-06 | PROGENICS PHARMACEUTICALS, INC. | $10,465 | Research payment | Cash or cash equivalent | PYLARIFY Drug, RADIOPHARMACEUTICAL | PYLARIFY PET-CT OR PET-MRI IN MEN WITH FAVORABLE INTERMEDIATE RISK -FIR- PROSTATE CANCER -MIRROR | 2024 |
| 2024-12-06 | Blueprint Medicines Corporation | $8,423 | Research payment | Cash or cash equivalent | A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis | 2024 | |
| 2024-12-06 | PFIZER INC. | $7,890 | Research payment | Cash or cash equivalent | TALZENNA Drug, ONCOLOGY | TALAPRO3 A PHASE 3 RANDOMIZED DOUBLEBLIND STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO WITH ENZALUTAMIDE IN MEN | 2024 |
| 2024-12-06 | Janssen Research & Development, LLC | $5,660 | Research payment | Cash or cash equivalent | DARZALEX Drug, Oncology | A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly D | 2024 |
| 2024-12-06 | Stryker Corporation | $1,500 | Research payment | Cash or cash equivalent | AEQUALIS PERFORM REVERSED Device, TRAUMA & EXTREMITIES | TORNIER PERFORM STEMLESS REVERSE IDE STUDY (19B-W-PERFORM-R) | 2024 |
| 2024-12-06 | ARGENX US, INC. | $1,450 | Research payment | Cash or cash equivalent | VYVGART HYTRULO Drug, Neurology | An Open-label Extension Study of ARGX-113-2009 to Evaluate the Long term Safety, Tolerability, and Efficacy of Efgartigi | 2024 |
| 2024-12-06 | Stryker Corporation | $1,242 | Research payment | Cash or cash equivalent | AEQUALIS PERFORM REVERSED Device, TRAUMA & EXTREMITIES | PERFORM HUMERAL SYSTEM STUDY (PHS) | 2024 |
| 2024-12-06 | Regeneron Pharmaceuticals, Inc. | $1,000 | Research payment | Cash or cash equivalent | DUPIXENT Biological, INFLAMMATION AND IMMUNOLOGY | A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF | 2024 |
| 2024-12-06 | HemoSonics LLC | $203 | Research payment | Cash or cash equivalent | QUNATRA QPLUS SYSTEM Device, HEMATOLOGY | Evaluation of the Clinical Performance of the Quantra System with the QSTAT Cartridge in Obstetric Patients | 2024 |
| 2024-12-05 | ABBVIE INC. | $25,285 | Research payment | Cash or cash equivalent | RINVOQ Biological, IMMUNOLOGY | A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participant | 2024 |
| 2024-12-05 | PFIZER INC. | $8,801 | Research payment | Cash or cash equivalent | A PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF 06939926 | 2024 | |
| 2024-12-05 | ABBVIE INC. | $8,094 | Research payment | Cash or cash equivalent | A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in Combination Wi | 2024 | |
| 2024-12-05 | Applied Medical Resources Corporation | $6,375 | Research payment | In-kind items and services | Alexis Orthopaedic Protector Device, ALEXIS PROTECTION & RETRACTION | 2024 | |
| 2024-12-05 | CSL Behring | $885 | Research payment | Cash or cash equivalent | HEMGENIX Biological, Hematology | Phase III, Open-label, Single-dose, Multi-center, Multinational Trial Investigating a Serotype 5 Adeno-associated Viral | 2024 |
| 2024-12-05 | PFIZER INC. | $880 | Research payment | Cash or cash equivalent | ADCETRIS Biological, Oncology | MULTIPLE PART CLINICAL TRIAL OF BRENTUXIMAB VEDOTIN IN CLASSICAL HODGKIN LYMPHOMA SUBJECTS | 2024 |
The latest 200 records of 2,581.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Salt Lake City, UT, county Salt Lake County, UT, state Utah; placed by its city name.
| Measure | Place (city or town) Salt Lake City, UT | County Salt Lake County, UT | State Utah |
|---|---|---|---|
| Population B01003 | 208,007 | 1,196,523 | 3,392,331 |
| Population, 2020 census P1 | 199,723 | 1,185,238 | 3,271,616 |
| Median age B01002 | 32.9 | 34.0 | 32.0 |
| Under 18 B01001 | 16.4% | 25.3% | 27.8% |
| 65 and over B01001 | 12.5% | 11.9% | 11.9% |
| Households B11001 | 92,652 | 426,245 | 1,124,822 |
| Foreign born B05002 | 14.9% | 13.5% | 8.9% |
| Median household income B19013 | $75,090 | $97,494 | $95,166 |
| Median family income B19113 | $109,291 | $116,682 | $109,675 |
| Per capita income B19301 | $51,173 | $45,106 | $40,873 |
| Poverty rate B17001 | 13.6% | 8.1% | 8.5% |
| Unemployment rate B23025 | 4.2% | 3.8% | 3.6% |
| Civilian labor force B23025 | 129,830 | 670,900 | 1,778,106 |
| Mean commute (minutes) B08013 | 19.5 | 22.3 | 22.1 |
| Bachelor's degree or higher B15003 | 51.5% | 39.4% | 37.7% |
| Housing units B25001 | 101,188 | 449,662 | 1,223,468 |
| Owner-occupied B25003 | 45.8% | 66.1% | 70.2% |
| Renters B25003 | 54.2% | 33.9% | 29.8% |
| Median home value B25077 | $539,500 | $525,700 | $489,400 |
| Median gross rent B25064 | $1,414 | $1,592 | $1,496 |
| White, not Hispanic B03002 | 64.4% | 66.6% | 74.7% |
| Black B03002 | 2.3% | 1.7% | 1.1% |
| Hispanic or Latino B03002 | 20.8% | 20.6% | 15.9% |
| Asian B03002 | 4.9% | 4.2% | 2.4% |
| American Indian and Alaska Native B03002 | 0.5% | 0.5% | 0.6% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Salt Lake City, UT.
Comments